More than 40 years ago, Hayflick and Moorhead discovered that normal human diploid fibroblasts (HDFs) cannot grow indefinitely in culture 1 . Rather, their proliferative capacities are intrinsically limited. After 60-80 population doublings in culture, HDFs stop dividing and adopt a phenotype characterized by large, flat cell size, a vacuolated morphology, inability to synthesize DNA and the presence of the senescence-associated β-galactosidase (SA-β-gal) marker 2 . We now know that the endpoint of this proliferative limit, termed replicative senescence, is due largely to erosion of telomeres, protective structures that cap the end of all eukaryotic chromosomes. Confirmation of this came from studies in which telomerase, the enzyme that maintains telomeres, was ectopically expressed in normal human somatic cells 3, 4 . Activation of telomerase results in telomere elongation, abrogation of replicative senescence, a normal karyotype and cellular immortalization. These results clearly demonstrate that telomere length determines the proliferative lifespan of HDFs, and that upregulation of telomerase activity (and hence telomere length) restores proliferative capacity.
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A large body of experimental evidence has demonstrated that telomere attrition contributes to tumorigenesis by promoting genome instability 5 . However, in the setting of a competent p53 pathway, mouse models have recently shown that telomere shortening is also tumour-suppressive by promoting replicative senescence to inhibit tumour formation. In this Review, we will discuss how telomeres shorten with cell replication and how this might initiate a DNA damage response (DDR) to induce replicative senescence (and cell death) and ultimately prevent tumorigenesis.
Telomeres and telomerase
Telomeres are composed of TTAGGG repeats, oriented 5′-to-3′ towards the end of the chromosome, ending in an essential 3′ single-stranded G-rich overhang. They are maintained by telomerase, a specialized ribonucleoprotein complex that includes an RNA template (TERC) and a reverse transcriptase catalytic subunit (TERT) (FIG. 1a) . The G-rich overhang is generated by post-replicative processing of the C-rich strand, and is the substrate for telomerase-mediated telomere elongation. Telomerase expression is low or absent in most human somatic tissues 6 , whereas it is robust in early proliferative progenitor germ and stem cells 7, 8 . In the absence of telomerase, each round of DNA replication is accompanied by telomere shortening owing to the failure of DNA polymerase to synthesize fully the extreme terminus of the lagging DNA strand. A total lifetime loss of ~2-4 kb in average telomere length has been observed in human cells [8] [9] [10] . Considering that human telomeres are only 8-12 kb in length or less at birth, this degree of attrition is significant over the natural lifespan of humans, and might be responsible for certain aspects of human ageing phenotypes 11 . Analysis of telomeres from a diverse array of organisms revealed that the telomere 3′ single-stranded overhang can invade the double-stranded telomeric tracts, displacing the homologous strand of the same telomere. Consequently, a telomere forms a lasso-like structure, termed the t loop, with a displacement (D) loop at the invasion site It has been proposed that the t loop has a crucial role in sequestering the 3′ end of telomeric DNA, preventing recognition by the DNA damage machinery as DNA double-strand breaks (DSBs) and initiation of inappropriate activation of DNA damage checkpoints.
Cytogenetic analyses of breakage and fusion of maize chromosomes provided the first evidence that telomeres maintain genome stability 14 . Mammalian telomeres associate with the shelterin complex of six core proteins: telomeric repeat-binding factor 1 (TRF1, also known as TERF1), TRF2 (also known as TERF2), TERF1-interacting nuclear factor 2 (TIN2, also known as TINF2), protection of telomeres 1 (PoT1), the PoT1-and TINF2-interacting protein (TPP1, also known as ACD) and the transcriptional repressor/activator protein RAP1 (also known as TERF2-interacting protein (TERF2IP)) (ReFs 15, 16) FIG. 1b) . Telomeres that can no longer exert end-protective functions are said to be dysfunctional, and these telomeres could arise either from progressive telomere attrition, or when components of the shelterin complex are perturbed, resulting in inappropriate chromosomal end-to-end fusions through the non-homologous end joining (NHEj) or homologous recombination (HR) DNA repair pathways 17 . one important cytogenetic distinction between these two repair processes is that the fusion points of chromosomes with naturally shortened telomeres do not normally possess telomeric DNA that is detectable by fluorescence in situ hybridization, whereas fused chromosomes resulting from loss of shelterin components frequently possess intense telomeric signals at the sites of fusion. NHEj and HR pathways account for the vast majority of chromosomal fusions, but other pathways of repair such as microhomology-mediated telomeretelomere recombination may also be involved, especially when the classic repair pathways are compromised [18] [19] [20] . These fusions are the basis of genomic instability associated with telomere dysfunction as they lead to anaphase bridging and subsequent breakage, which requires further repair. Repetition of this breakage-fusion-bridge cycle leads to aneuploidy and further fusions and, depending on how such DNA damage is resolved, it has been hypothesized that loss of heterozygosity or gene amplification could result in tumorigenesis 5, 21 .
Telomere dysfunction initiates a DDR Biochemical analyses revealed that HDFs that entered replicative senescence display molecular markers characteristic of cells bearing DNA DSBs, suggesting that dysfunctional telomeres elicit a potent DDR 22 . These markers of the DDR include phosphorylated γ-H2AX, p53-binding protein 1 (TP53BP1), NBS1 (also known as nibrin), MDC1 and CHK2. Many of these proteins localize directly to dysfunctional telomeres to form dysfunctional telomere-induced foci, and their inactivation in senescent cells restores cell cycle progression into S-phase 22, 23 . These results suggest that dysfunctional telomeres are recognized as DSBs that impinge on p53 and/or RB tumour suppressor pathways to induce expression of their regulators p21 (encoded by CDKN1A) and INK4A (also known as p16 and encoded by CDKN2A) to initiate replicative senescence [24] [25] [26] . Dysfunctional telomeres activate upstream checkpoint phosphatidylinositol 3-kinase-like kinases (PIKKs), such as ATM (ataxia-telangiectasia mutated) or ATR (ataxia telangiectasia-and Rad3-related) 22, [27] [28] [29] [30] (FIG. 2) . once activated, these kinases phosphorylate downstream factors, including CHK1 and CHK2, that in turn phosphorylate p53 (ReF. 29) . Phosphorylation of p53 results in the displacement of the murine double minute 2 (MDM2) protein, liberating p53 from degradation, and stimulation of the expression of the cyclin-dependent kinase inhibitor p21. p21 inhibits cell cycle progression by inhibiting cyclin-dependent kinases that phosphorylate and inactivate RB. In addition to promoting cell cycle arrest, dysfunctional telomeres can also activate p53-dependent apoptosis, as mice bearing dysfunctional telomeres show increased apoptosis in proliferative cells [31] [32] [33] . In the setting of a competent p53 pathway, dysfunctional telomeres appear to function as potent tumour suppressors by engaging cellular pathways that activate replicative senescence and/or apoptosis to inhibit tumour formation. Therefore, it is not surprising that p53 loss results in a permissive environment that favours proliferation and survival of genomically damaged cells and the eventual progression to cancer. The role of the INK4A-RB pathway in mediating the telomere DDR is less clear
.
Inactivation of p53 and RB by antisense oligonucleotides 34 or by viral oncoproteins 35 can extend replicative potential in HDFs, driving further telomere erosion and culminating in a period of massive cell death and rampant genomic instability that is termed crisis. Crisis serves as a second, p53-independent checkpoint in tumour suppression and is characterized by multiple chromosomal fusions 36 . virally transformed human cells that eliminate p53 and/or RB function can escape crisis at low frequencies, and invariably adopt telomeremaintenance programmes: 80-90% of human tumours have some telomerase activity, and the remainder maintain telomeres by a recombination-mediated process termed AlT (alternative lengthening of telomeres) [37] [38] [39] [40] . Together, these observations support the view that replicative senescence and crisis provide potent barriers to tumour development and, by extension, that proper telomere maintenance is an essential aspect of full malignant transformation.
At a glance
• Telomeres are TTAGGG repetitive sequences that cap the ends of eukaryotic chromosomes.
• A core of telomere binding proteins, termed the shelterin complex, serve to protect telomeric ends.
• Critical telomere shortening or uncapping of telomere binding proteins results in telomere dysfunction.
• Dysfunctional telomeres activate a DNA damage response. In the setting of a competent p53 pathway, this initiates senescence and apoptotic programmes to inhibit tumorigenesis.
• In cells with mutant p53, dysfunctional telomeres promote genome instability and progression to cancer.
• Cellular senescence is as potent as apoptosis in suppressing spontaneous tumorigenesis in mouse models of telomere dysfunction. Nature Reviews | Cancer 
Dicentric chromosome
A chromosome that has two centromeres, formed by breakage and reunion of two chromosomes.
Dysfunctional telomeres, p53 and tumorigenesis
Telomere dysfunction has been proposed to fuel tumorigenesis, as, depending on how dicentric chromosomes are resolved in the breakage-fusion-bridge cycle, loss of heterozygosity of tumour suppressors and/or amplification of oncogenes could result in a pro-cancer genotype 5 . The cloning of the gene encoding Terc enabled the construction of the telomerase-knockout mouse to formally test this hypothesis in vivo 41, 42 . The telomerasedeficient mouse lacks the crucial RNA subunit Terc, is viable and fertile, and has no significant morphological abnormalities 42 . To drive telomeres to shorter and potentially dysfunctional lengths in later generations, successive Terc -/-intercrosses were instituted. By the sixth generation (G6), increased apoptosis and compromised function were observed in highly proliferative tissues, including skin, haematopoietic tissue and reproductive systems 31, [42] [43] [44] . loss of haematopoietic function probably stems from accumulation of damaged DNA as a result of dysfunctional telomeres 45 . Importantly, despite the presence of critically short telomeres, removal of p53 function rescued many of the cellular defects, including growth arrest in cell culture, testicular atrophy and intestinal and germ-cell apoptosis 46 . Cell culture transformation assays showed that Trp53-null cells with critically shortened telomeres exhibited increased susceptibility to transformation by Myc and Hras. Similar findings were observed in vivo: the progressive decline in telomere function correlated with increased tumour incidence and decreased survival. Therefore, in the absence of Trp53, telomere dysfunction and the resultant genomic instability promote tumorigenesis.
As a further demonstration of the effect of p53 status on dysfunctional telomere-induced tumour growth, late-generation Terc -/-;Trp53 +/-mice emerged with a tumour range that strikingly resembled those of aged humans: carcinomas of the skin, breast and intestine with cytogenetic hallmarks of telomere dysfunction emerged as the largest group of tumours 47 .
Together, these findings demonstrate that telomere dysfunction promotes the development of cancer in the setting of p53 deficiency, and further reinforce the importance of an intact p53 pathway in tumour inhibition in the setting of telomere dysfunction.
To further examine how dysfunctional telomeres cooperate with p53 activation to limit neoplastic growth in vivo, mouse models bearing deletions of various tumour suppressor genes were mated with telomeraseknockout mice (TABLe 1) . For example, the CDKN2A locus encodes the INK4A and ARF tumour suppressors. Both genes share a common second exon that is deleted in the Cdkn2a -/-mouse 48 . These mice often develop lymphomas and sarcomas, and importantly, the pathway resulting in activation of p53 through DNA damage is intact in these animals 25 .
Treatment of early-generation Terc -/-

;Cdkn2a
-/-mice with DMBA and ultraviolet B revealed that these mice are cancer-prone. However, similar treatment of G6 Terc -/-;Cdkn2a -/-mice that have short dysfunctional telomeres yielded a marked reduction in tumour incidence (from 64% to 31%) and much longer survival 49 . Primary fibroblasts isolated from these embryos also exhibited resistance to transformation by Myc and Hras. A similar finding was observed in a chemical carcinogenesis skin cancer model, in which late-generation Terc -/-mice produced 20-fold fewer skin tumours than wild-type controls with long telomeres 50 . In addition, stablization of p53 was detected in late-generation Terc -/-papillomas. Taken together, these results suggest that dysfunctional telomeres inhibit tumour initiation in vivo in the setting of an intact DNA damage-induced p53 signalling pathway, either by activating p53-dependent apoptosis or replicative senescence.
The link between telomere shortening and tumour suppression is further highlighted in the dysfunctional telomeres. Similar results were observed in p53-competent mouse models of hepatocellular carcinoma, in which dysfunctional telomeres served to initiate tumour growth, but also limited the size of these tumours (that is, their progression) by activating apoptosis 53 .
short telomeres and p53-dependent senescence The mouse models discussed above all express wild-type p53, which is capable of inducing both apoptosis and/or senescence, so it remained unclear how dysfunctional telomeres limit neoplastic growth in vivo. Although apoptosis clearly has a tumour-suppressive role in vivo, until recently it was not clear whether p53-dependent replicative senescence had a role in tumour suppression in vivo. Several reasons account for why replicative senescence was not initially recognized as a tumour suppressor mechanism in vivo. First, as laboratory mice normally have long telomeres, it was not clear whether a replicative senescence mechanism existed in mice. Second, compared with apoptosis, it is relatively difficult to reliably detect the presence of senescent cells in vivo. until recently, only the SA-β-gal assay was available to mark senescent cells. However, there are now several promising markers to detect both senescent mouse and human cells in vivo [54] [55] [56] . Two recent studies specifically examined the role of telomere-induced replicative senescence as a mechanism of tumour suppression in the telomerase-knockout mice (FIG. 3) . The first study looked at lymphoma development in the context of telomere dysfunction using the established Eµ-Myc transgenic model for Burkitt lymphoma 57 . 
A second approach to examining the role of cellular senescence in tumorigenesis used a knock-in mouse with a single amino acid mutation (Arg172Pro) within the p53 protein 58 . Cells harbouring this mutation (Trp53 P/P ) are incapable of activating p53-dependent apoptosis 59 , but the p53-dependent cellular senescence pathway is intact as induction of telomere dysfunction through overexpression of a dominant-negative TRF2 in these cells led to dramatic reduction of cellular proliferation and the appearance of senescent cells that stained positive for SA-β-Gal 58 . To genetically dissect the contribution of p53-dependent apoptosis versus cellular senescence to tumour suppression in the setting of telomere dysfunction in vivo, an intergenerational (iG) mating scheme was used to generate four cohorts of mice: Terc 
Box 1 | The shelterin complex
The shelterin complex 15 is composed of telomeric-repeat binding factor 1 (TRF1), TRF2, TERF1-interacting protein 2 (TIN2), protection of telomeres 1 (POT1), the POT1-and TINF2-interacting protein TPP1 and the transcriptional repressor/ activator protein RAP1. Proteins that directly bind the double-stranded telomeric repeats include TRF1 and TRF2. TRF1 is a negative regulator of telomere length whereas TRF2 has important roles in preventing a DNA damage response (DDR) at telomeres. POT1 belongs to a family of evolutionarily conserved oligosaccharide/ oligonucleotide-binding (OB) fold-containing proteins and specifically recognizes the single-stranded G-overhang [78] [79] [80] [81] . Shelterin components that do not bind telomeric DNA directly include TIN2, which associates with TRF1 and TRF2, and TPP1, which forms a heterodimer with POT1 (ReFs 82,83). RAP1 is recruited to telomeres by TRF2 and negatively regulates telomere length. Depletion of endogenous TRF2 levels, either by overexpression of dominant-negative TRF2 (TRF2-DN) or through genetic knockout approaches in mouse cells with long telomeres, results in massive chromosomal fusions with telomeric sequence at the sites of fusions. Mouse models in which shelterin components have been deleted experience telomere dysfunction, a DDR, and chromosomal fusions resembling those observed in telomerase-null mice 79, 81, [84] [85] [86] [87] [88] . These results suggest that both critically short telomeres and direct disruption of the shelterin structure can initiate telomere dysfunction and trigger a DDR and chromosomal fusions. ;Trp53 P/P mice. Taken together, both studies suggest that p53-dependent apoptosis is dispensable for mediating telomere-dependent spontaneous tumour suppression in vivo. Instead, the p53-p21-dependent cellular senescence pathway is potently activated in mice bearing dysfunctional telomeres, and might be responsible for the tumour suppression observed in these animals. one surprising result is the failure of the iG1 Terc -/-; Trp53 P/P mouse to suppress tumorigenesis in a DMBA skin carcinogenesis model 58 . This is in sharp contrast to the strong tumour suppression observed in lategeneration Terc -/--null mice with intact p53 function 50 . one explanation is that although telomere-induced cellular senescence is capable of suppressing spontaneous tumorigenesis from mesenchymal tumours, it is insufficient to suppress cancer formation of epithelial tissues such as the skin. This notion that p53 is able to activate different checkpoint programmes in different tissues is supported by the observation that restoration of endogenous p53 function in p53-null mice activates primarily an apoptotic response to inhibit T-cell lymphomas, whereas inhibition of sarcomas requires activation of a cellular senescence programme 60 .
From the results presented above, one would hypothesize that telomere dysfunction in the absence of p21 would abrogate the senescence response in vivo, resulting in accelerated tumour formation. Surprisingly, this was not the case: late-generation Terc -/-;Cdkn1a -/-mice do not show increased chromosomal instability nor do they succumb to increased tumorigenesis 61 . Instead, loss of p21 extended the lifespan of the mice and rescued cellular proliferative defects due to dysfunctional telomeres, presumably owing to reduced entry of proliferative cells into cellular senescence. The fact that tumorigenesis is not increased in the context of p21 deficiency indicates that, in this mouse model, p53-mediated apoptosis functions as a redundant anti-tumour barrier in response to short telomeres. Genetic abrogation of p21 in Terc-null;p53 R172P mice will test this possibility, as loss of p21 would inhibit p53-mediated cellular senescence, whereas the presence of the p53 R172P allele would abrogate p53-dependent apoptosis. This mouse should therefore resemble Trp53 -/-mice and be tumour prone. However, the age-dependent increases in apoptosis in certain tissues were not altered in Terc -/-;Cdkn1a -/-mice, suggesting it is possible that p53-dependent but senescenceand apoptosis-independent effects of dysfunctional telomeres might account for some of the observed tumour Figure 2 | Telomere dysfunction activates the p53 and rB pathways. Progressive telomere shortening or uncapped telomeres initiate a DNA damage response, resulting in the activation of ataxia telangiectasia mutated (ATM) and ataxia telangiectasia-and Rad3-related (ATR), and downstream kinases CHK1 and CHK2, and phosphorylation of p53. Phosphorylated p53 transcriptionally upregulates genes that mediate cellular senescence and/or apoptosis to inhibit tumorigenesis. Depending on how telomeres are uncapped, removal of telomeric-repeat binding factor 2 (TRF2) preferentially engages an ATM-dependent checkpoint, whereas removal of POT1 preferentially engages ATR. Although less well-understood, telomere dysfunction could also activate the INK4A-RB pathway and inhibit cellular proliferation. CDK, cyclin-dependant kinase; ds, double strand; ss, single strand.
Box 2 | InK4A and a telomere-induced DnA damage response
The role of the INK4A-RB pathway in mediating the telomere DNA damage response (DDR) is not clear. INK4A is a cyclin-dependent kinase inhibitor that is markedly increased in senescent cells and results in RB hypophosphorylation 89 . Expression of telomerase reverse transcriptase (TERT) in human diploid fibroblasts (HDFs) prevents INK4A induction, suggesting that TERT prevents formation of dysfunctional telomeres that would otherwise activate INK4A. Support for this hypothesis comes from experiments in which treatment of HDF with dominant-negative telomeric-repeat binding factor 2 (TRF2-DN) induces INK4A protein levels and entry into senescence, suggesting that, in addition to p53, INK4A could be a second effector of the telomere DDR 90 . However, compared with the DDR-mediated p53 checkpoint, the kinetics of telomere DDR-mediated INK4A are slow. As telomere-induced focus formation occurs relatively transiently, this slow induction of an INK4A damage response could explain why telomere-induced foci were not observed in senescent HDFs with increased INK4A levels 91 . Interestingly, INK4A does not appear to be an important effector of the telomere DDR in mouse embryo fibroblasts (MEFs), as MEFs lacking p53 are completely refractory to the effects of TRF2-DN irrespective of INK4A levels 92 . However, it is not clear whether this is a unique property of MEFs or a general property of DDR signal transduction wiring differences between mouse and man. Mouse models of p21 and p53 deficiency rescue some of the degenerative phenotypes of late-generation telomerase-null mice 46, 61 ; INK4A deficiency does not 93 . However, the Cdkn2a-knockout mouse compromises the function of both INK4A and ARF, resulting in impingement of both the RB and p53 pathways. A mouse model that examines how telomere-initiated DDR is perturbed in the setting of INK4A deficiency only in vivo is required.
suppression in vivo. It would be interesting to test the hypothesis that p53-mediated autophagy contributes to tumour suppression in the setting of telomere dysfunction 62 . Taken together, the above studies suggest that activation of either an apoptosis or a senescence pathway is sufficient to block tumorigenesis in most tissues. It also appears that when one anticancer pathway is selectively eliminated, the other one can serve as a back-up. In carcinomas, perhaps activation of both senescence and apoptotic pathways are required to enforce tumour suppression. How cells are ushered to undergo either apoptosis or/and cellular senescence in response to telomere dysfunction remains an important question to address in the future. Therapeutic strategies that target telomeres The demonstration that dysfunctional telomeres could engage a senescence program to suppress tumorigenesis in vivo suggests possible future therapeutic applications 63 . The upregulation of telomerase in most human cancers and its requirement for proliferation make antitelomerase compounds a potential means to induce telomere shortening and initiation of a senescence programme in tumour cells 64 . For example, treatment of HT1080 fibrosarcoma cell lines with the telomerase inhibitor BIBR1532 results in progressive telomere shortening, induction of a senescence phenotype and inhibition of tumour growth when transplanted into recipient mice 65 . GRN163l is a modified oligonucleotide complementary to TERC and a potent and specific telomerase antagonist 66 . GRN163l effectively inhibits the telomerase activity of various human cancer cell lines [67] [68] [69] [70] , resulting in progressive telomere shortening and induction of cellular senescence to suppress tumour cell growth in vitro. Furthermore, administration of GRN163l is effective in preventing lung metastases in breast cancer xenograft animal models 68 . In addition to telomerase, targeting components of the shelterin complex such as TPP1 or PoT1 to induce a DDR might also induce the onset of cellular senescence. The G-rich strand of telomeric DNA can fold into a four-stranded G-quadruplex (G4), stabilization of which perturbs telomere function. The G4-inducing ligand RHPS4 triggers a potent DDR at telomeres specifically in transformed human fibroblasts and melanoma cells 71 . Interestingly, telomere-induced focus formation correlated with delocalization of PoT1 and was antagonized by overexpression of PoT1 or TRF2. In mice, RHPS4 exerted its anti-tumour effect on xenografts of diverse human tumour cell lines. These data provide encouraging evidence that telomere dysfunction initiates a DDR in malignant cells to suppress tumorigenesis. conclusions understanding the molecular mechanisms that limit neoplastic growth could provide insights into novel anticancer therapies. Telomere-induced cellular senescence has long been hypothesized to contribute to tumour suppression 72 . However, this process is typically studied in cultured cells, and how it contributes to tumour suppression in vivo has been poorly defined. The mouse studies outlined above provide the first direct evidence that dysfunctional telomeres initiate p53-dependent cellular senescence to suppress spontaneous tumorigenesis in vivo. Surprisingly, p53-dependent apoptosis appears largely dispensable for spontaneous tumour suppression when the senescence pathway is activated, thereby placing cellular senescence on an equal footing with apoptosis in mediating tumour suppression.
Dysfunctional telomere-induced senescence was accompanied by increases in senescence markers, including p53, p21, p15 and SA-β-gal activity, suggesting that a DDR is activated by dysfunctional telomeres in vivo. Recent observations indicate that both telomere dysfunction 73, 74 and the DDR 75, 76 are activated at the earliest stages in many human carcinomas. The results presented would predict that activation of an intact DDR pathway by dysfunctional telomeres in premalignant lesions would engage cellular senescence or apoptotic pathways, suppressing further tumour progression. However, the increased genome instability in nascent tumour cells that stochastically inactivate components of the DDR pathways would promote tumour progression.
Although there is still much to learn about whether anti-telomerase therapy would be efficacious against human cancers, it is encouraging to see promising new drugs enter clinical trials. However, several limitations for this class of drugs remain. For anti-telomerase drugs to engage p53-dependent apoptotic and/or senescence pathways to suppress tumorigenesis, an intact p53 pathway is required to effectively inhibit cancer cell growth, a daunting scenario considering that p53 is mutated in approximately 50% of all human cancers. one must also be concerned about the possibility that tumour cells rendered senescent would yield secretory products that might themselves be tumour-promoting 77 . Finally, this therapy might not work in AlT tumours, which lack functional telomerase. Further progress in our understanding of the basic biology of telomeres should enable us to circumvent these problems. ) or by overexpressing the BCL2 oncogene, eliminates apoptosis but cellular senescence remains intact. In the absence of apoptosis, cellular senescence is able to potently inhibit both spontaneous and oncogene-mediated tumour formation in vivo. WT, wild-type.
